|
|
|
|
Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project
- Biovitrum AB and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for future prevention of Hemolytic Disease of the Newborn (HDN) that can...
|
|
|
Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project
Biovitrum AB (publ) (STO:BVT) and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for future prevention of Hemolytic Disease of the Newborn ...
|
|
|
Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh- immunization Prevention Project
Biovitrum AB (publ) (STO: BVT) and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for future prevention of Hemolytic Disease of the Newborn...
|
|
|
Researchers to Present Additional Data on Soliris (eculizumab) for the Treatment of PNH at the ASH Annual Meet
/PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc.today announced that the American Society of Hematology (ASH) has published additional data relating to Soliris(R) (eculizumab) as a treatment for patients with paroxysmal nocturnal...
|
|
|
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual M
Initial Physician Experience with Eculizumab in Patients with Other Rare Complement-Mediated Diseases also to be Presented CHESHIRE, Conn., Nov.10 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that the American...
|
|
|
Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual M
Initial Physician Experience with Eculizumab in Patients with Other Rare Complement-Mediated Diseases also to be Presented CHESHIRE, Conn., Nov.10 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that the American...
|
|
|
GeneThera - CHANGING DIRECTIONS - an Update to Shareholders
WHEAT RIDGE, Colo., Nov.3 /PRNewswire-FirstCall/ -- GeneThera, Inc. , As a service and responsibility to our shareholders, GeneThera is publicly outlining our strategy for the future of the company. GeneThera is making a pivotal shift...
|
